Detalhe da pesquisa
1.
Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data.
Cardiovasc Diabetol
; 21(1): 282, 2022 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36522650
2.
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
Cardiovasc Diabetol
; 21(1): 104, 2022 06 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35689214
3.
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Diabetes Obes Metab
; 24(7): 1277-1287, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35322567
4.
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Cardiovasc Diabetol
; 20(1): 159, 2021 07 31.
Artigo
Inglês
| MEDLINE | ID: mdl-34332558
5.
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Diabetes Obes Metab
; 23 Suppl 2: 19-27, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33835641
6.
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Diabetes Obes Metab
; 23(1): 75-85, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32893440
7.
Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men.
Stroke
; 51(5): 1435-1441, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32268850
8.
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Diabetes Obes Metab
; 22(9): 1607-1618, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32363737
9.
Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men.
Stroke
; 50(1): 155-161, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30580727
10.
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Diabetes Obes Metab
; 21(12): 2651-2659, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31379124
11.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Diabetes Obes Metab
; 21(5): 1136-1145, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30609272
12.
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Diabetes Obes Metab
; 21(4): 968-974, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30537226
13.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Circulation
; 136(3): 249-259, 2017 Jul 18.
Artigo
Inglês
| MEDLINE | ID: mdl-28522450
14.
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Diabetes Obes Metab
; 20(2): 344-351, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28771923
15.
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Diabetes Obes Metab
; 20(8): 1983-1987, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29569378
16.
Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men.
BMC Pulm Med
; 18(1): 118, 2018 Jul 18.
Artigo
Inglês
| MEDLINE | ID: mdl-30021542
17.
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(6): 831-841, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28116795
18.
Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men.
Blood Press
; 26(4): 229-236, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28276720
19.
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013.
Diabetologia
; 59(8): 1692-701, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27189067
20.
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
Am Heart J
; 178: 85-94, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27502855